AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02006875 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS
Description: Interventions started on the next weekday after pretest and were performed once a day for 15 consecutive weekdays. Participants in the E and C groups received rTMS (either real or sham, 1 Hz, 15 minutes), followed by a session of physical therapy for 45 minutes.
Study NCT01907139 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Robot-assisted therapy
Description: Instrumentation of the ArmeoSpring with position sensors at each joint enables it to be used as a 3D input device for computer game play with the hemiparetic arm. Games were designed to simulate functional arm movements to provide training in a simple virtual reality environment. Vu Therapy games were developed with the goal of enabling repetitive task-specific practice including grocery shopping, cleaning a stovetop, and playing basketball. In this way, stroke patients who are unable to use their severely weakened arms in a functional way are able to practice task-specific movements in a simulated, gravity-reduced environment. Auditory and visual feedback is provided throughout game play to maintain the patient's attention and motivation. In addition, users are provided objective feedback of task performance at the end of each game to enhance motivation and awareness of progress.
Study NCT01907139 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distributed constraint-induced therapy
Description: The dCIT group will focus on restriction on movement of the unaffected hand by placement of the hand in a mitt for 6 hours/day and intensive training of the affected UL in functional tasks for 1.5 hours/weekday over the 4 weeks. Participants in this group will focus on the intensive training of the affected arm in functional activities with behavioral shaping. The shaping techniques will involve individualized task selection, graded task difficulty (e.g., practicing deficient parts of the selected activity and then performing the entire activity), verbal feedback, prompting, physical assistance with movements, and modeling. The level of challenge will be adapted based on patient ability and improvement. Participants will be also required to place their unaffected hand and wrist in a mitt for 6 hours a day during the 4-week period and document mitt compliance in daily logs.
Study NCT01907139 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dose-matched control therapy
Description: The DMCT group mediated by the therapists will be designed to control for the duration of therapy in amount of therapy hours. This group will received a structured protocol using conventional occupational therapy techniques such as neuro-developmental techniques with emphasis on functional tasks and muscle strengthening. The treatment protocol will include (1) passive range of motion exercises, stretching of the affected limb, or facilitatory and inhibitory techniques for 15 to 20 minutes, (2) tasks for training fine motor or dexterous function for 20 minutes, (3) arm exercises or gross motor training for 20 minutes, (4) muscle strengthening of the affected UL for 15 to 20 minutes, and (5) activities of daily living or functional tasks practice for 15 to 20 minutes. The activities will be adapted based on the level of motor impairment and individual needs of the patients.
Study NCT04146896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NYX-2925 50 mg
Description: NYX-2925 administered orally
Study NCT04146896 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered orally
Study NCT02835846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estrogen Cream
Description: Participants are provided a vaginal estrogen cream (i.e., Premarin Cream® 0.625 mg conjugated estrogen/gram) and instructed to use 0.5 grams with an applicator twice weekly for 12 weeks.
Study NCT03586661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Given IV
Study NCT03586661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Given PO
Study NCT03258580 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medoc thermal stimulator
Description: Heat pain stimulation for substudy 1
Study NCT03258580 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electric shock stimulator
Description: Electric pain stimulation for substudy 1
Study NCT03258580 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cold water bath
Description: Cold pain stimulation for substudy 1
Study NCT03258580 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain assessment performance feedback
Description: Participants in substudy 3's Feedback Group will be informed about their performance after every trial when making judgments about other people's pain.
Study NCT02609776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: The first cohort of participants will receive IV infusions of Amivantamab 140 mg as monotherapy. Each subsequent cohort will receive IV infusions of Amivantamab at increased dose level until maximum tolerated dose is reached or all planned doses are administered. Participants will receive lazertinib and Amivantamab at predefined dose levels, based upon observed safety and protocol defined criteria. The duration of each treatment cycle is 28 days. In Chemotherapy Combination Cohort, participants will receive Amivantamab, administered on a 21-day cycle, in combination with the administration of standard of care carboplatin and pemetrexed.
Study NCT02609776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Participants will receive IV infusion of Amivantamab as monotherapy at RP2D regimen or in combination lazertinib at RP2CD regimen as determined in Part 1.
Study NCT02609776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib
Description: Lazertinib will be administered in combination with Amivantamab at predefined dose levels, based upon observed safety and protocol defined criteria. Lazertinib will be administered daily on the 28-day Amivantamab treatment cycle.
Study NCT02609776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Participants will receive carboplatin in combination with pemetrexed and Amivantamab as an IV infusion on 21-day treatment cycle in Part 1 Chemotherapy Combination Cohort only.
Study NCT02609776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Participants will receive pemetrexed in combination with carboplatin and Amivantamab as an IV infusion on 21-day treatment cycle in Part 1 Chemotherapy Combination Cohort only.
Study NCT03767244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Participants will receive apalutamide 240 mg (4 tablets of 60 mg each) orally once daily.
Study NCT03767244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen Deprivation Therapy (ADT)
Description: Participants will receive a stable regimen of ADT - gonadotropin-releasing hormone analog (agonist or antagonist) (GnRHa). ADT is a kind of hormone therapy for prostate cancer. GnRHa will be administrated to achieve and maintain sub-castrate concentrations of testosterone (50 nanogram per deciliter \[ng/dL\]).
Study NCT03767244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo oral tablets daily.
Study NCT04397276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-70218902
Description: JNJ-70218902 will be administered.
Study NCT04175600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selexipag
Description: Selexipag tablet will be administered orally.
Study NCT04175600 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets will be administered orally.
Study NCT02566668 — intervention group
Intervention type: OTHER
Intervention: 1 year Observational Follow-up
Description: Approximately 12 months after research bronchoscopy, subjects will return for follow-up visit.
Study NCT03104491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inotuzumab Ozogamicin
Description: Inotuzumab ozogamicin, IV, 28 day cycles~Phase 1 dosages:~Dose Level -2 (0.1 mg/m\^2)~Dose Level -1 (0.2 mg/m\^2)~Dose Level 0 (0.3 mg/m\^2)~Dose Level 1 (0.4 mg/m\^2)~Dose Level 2 (0.5 mg/m\^2)~Dose Level 3 (0.6 mg/m\^2)
Study NCT03291028 — intervention group
Intervention type: BIOLOGICAL
Intervention: Immune checkpoint inhibitor targeting PD1
Description: RCC and UC patients treated with immune checkpoint blockade
Study NCT01320943 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDF
Description: Tenofovir disoproxil fumarate (TDF) 300 mg tablet administered orally once daily
Study NCT01320943 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stop TDF
Description: Participants will stop TDF therapy
Study NCT01108393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Agomelatine A
Description: Agomelatine 25 mg film-coated tablet~Agomelatine 2x25mg film-coated tablet
Study NCT01108393 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02816086 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interdisciplinary collaboration structure
Description: A pharmacist is integrated in the team surrounding the patient, working by the Integrated Medicines Management (IMM) model. The IMM-model consist of medication reconciliation, medication review, standardized medication reports and counseling patients about their medication at discharge. In addition a phone meeting between the primary care physician and the study pharmacist is added after discharge.
Study NCT01218529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Co-administration of lapatinib 1250mg once daily during the WBRT period (2 weeks)and then monotherapy with lapatinib 1500mg once daily for 4 weeks.
Study NCT03891953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DKY709
Description: Novel immunomodulatory agent
Study NCT03891953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: PDR001 is a high-affinity, ligand-blocking, humanized IgG4 monoclonal antibody directed against PD-1 that blocks the binding of PD-L1 and PD-L2
Study NCT03937219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Specified dose on specified days.
Study NCT03937219 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Specified dose on specified days.
Study NCT03937219 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days.
Study NCT03937219 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Specified dose on specified days.
Study NCT03937219 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days.
Study NCT03937219 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabozantinib-matched placebo
Description: Specified dose on specified days.
Study NCT02106988 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation therapy delivered for a total dose of 50.4 to 54 Gy 5 days a week for 28 to 30 treatments.
Study NCT02106988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg by vein Days 1-3 in a 21 day cycle.
Study NCT02106988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide phosphate
Description: 67 mg/m2 by vein on Days 1-3 of a 21 day cycle.
Study NCT02106988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: 1 g/m2 by vein on Days 1-3 of a 21 day cycle.
Study NCT02106988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: 0.4 g/m2 by vein on Days 1-3 with Ifosfamide, 0.6 g/m2 by vein over 24 hours daily on Days 1-3 via ambulatory pump.
Study NCT02106988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: 200 mg/m2 by vein on Day 1 of a 21 day cycle.
Study NCT04502550 — intervention group
Intervention type: DRUG
Intervention: Propofol
Description: Target effect-site concentration of propofol will be started at 1.4 μg/mL and will be increased by 0.3 μg/mL with reassessment until endpoints are achieved.
Study NCT03635489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m\^2 IV infusion on Day 1 of each 21-day cycle.
Study NCT03635489 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: 175 mg/m\^2 IV infusion on Day 1 of each 21-day cycle.
Study NCT03635489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg IV infusion on Day 1 of each 21-day cycle.
Study NCT03635489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Area Under the Curve (AUC) of 6 mg/ml/min on Day 1 of each 21-day cycle.
Study NCT03635489 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Area Under the Curve (AUC) of 6 mg/ml/min on Day 1 of each 21-day cycle.
Study NCT03635489 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to bevacizumab IV infusion on Day 1 of each 21-day cycle.
Study NCT03501329 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Biological,Psychological and Social support
Study NCT01741116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TKI258
Description: Investigational treatment refers to TKI258 in this study Until Progression, unacceptable toxicity, withdrawal
Study NCT00925821 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic stem cell transplant versus second autologous transplantation
Description: Transplantation of stem cells from a MRD or MUD, respectively after dose-reduced conditioning versus autologous stem cell graft after preparation with melphalan 200 mg/m²
Study NCT00925821 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: allogeneic stem cell transplant versus second autologous transplantation
Description: Transplantation of stem cells from a MRD or MUD, respectively after dose-reduced conditioning versus autologous stem cell graft after preparation with melphalan 200 mg/m²
Study NCT00925821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD
Description: After enrollment, patients are to receive four cycles of RAD induction treatment: a combination of lenalidomide (Revlimid), adriamycin, and dexamethasone.
Study NCT00925821 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RAD
Description: After enrollment, patients are to receive four cycles of RAD induction treatment: a combination of lenalidomide (Revlimid), adriamycin, and dexamethasone.
Study NCT01547299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Study NCT01547299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide
Study NCT01547299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride
Study NCT03145571 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Continuity of midwifery care
Description: Pre-natal care in rural villages performed by the midwives from the local hospital
Study NCT03682705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elsubrutinib
Description: Elsubrutinib capsule will be administered orally.
Study NCT03682705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Upadacitinib tablet will be administered orally.
Study NCT03682705 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for elsubrutinib
Description: Placebo capsule for elsubrutinib will be administered orally.
Study NCT03682705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for elsubrutinib
Description: Placebo capsule for elsubrutinib will be administered orally.
Study NCT03682705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for upadacitinib
Description: Placebo tablet for upadacitinib will be administered orally.
Study NCT03682705 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for upadacitinib
Description: Placebo tablet for upadacitinib will be administered orally.
Study NCT03392207 — intervention group
Intervention type: BIOLOGICAL
Intervention: Seasonal Influenza Vaccine
Description: Trivalent, Fragmented, Inactivated Seasonal Influenza Vaccine (2018 Southern Hemisphere Season) produced at Butantan Institute
Study NCT03489018 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV10
Description: Experimental arms will receive a lower dose of the intervention than the marketed dose.
Study NCT02162303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: 0.6 mg a day of active treatment or placebo for 24 weeks
Study NCT02162303 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar,given once daily, over 6 months.To mimic active treatment
Study NCT02094521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0113-0987
Description: For oral administration. All subjects will be treated for 10 consecutive days with five days on 5 mg NNC0113-0987 followed by five days on 10 mg NNC0113-0987. Dose escalation is chosen to increase gastrointestinal tolerability.
Study NCT02629211 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NaviAid™ AB
Description: NaviAid™ AB Procedure
Study NCT04244851 — intervention group
Intervention type: OTHER
Intervention: Malnourished patients
Description: Data of included patients will be recorded during hospitalization using medical charts.~Every patient will be contacted by phone 3 months after hospital discharge. A sample of patients and their caregivers will be interviewed to better understand their perception of malnutrition and what they need to better take care of malnutrition.
Study NCT00628836 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BION stimulation
Description: The study will have two phases, each with a six week duration. During phase 1, the BION group will be implanted with BIONs in the middle deltoid and supraspinatus muscles. The muscles will be stimulated electrically by way of the BION and an external controller for one to two hours per day at 5pps in an on-off duty cycle train. The SE group will begin surface stimulation similar to that of BE group.~Subjects in either group whose initial therapy in phase 1 successfully reduces the amount of shoulder subluxation to 5mm or less will go off stimulation for six weeks, and be reassessed whether subluxation is redeveloping.~If a subject in either group does not respond sufficiently to phase 1 therapy, the participant will move to phase 2 where the shoulder will be stimulated at up to 25 pps either with surface stimulation (SE group) or BION stimulation (BE group) for another six weeks. At the end of phase 2, participants will go off stimulation for six weeks and then be reevaluated.
Study NCT00628836 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BION stimulation
Description: The study will have two phases, each with a six week duration. During phase 1, the BION group will be implanted with BIONs in the middle deltoid and supraspinatus muscles. The muscles will be stimulated electrically by way of the BION and an external controller for one to two hours per day at 5pps in an on-off duty cycle train. The SE group will begin surface stimulation similar to that of BE group.~Subjects in either group whose initial therapy in phase 1 successfully reduces the amount of shoulder subluxation to 5mm or less will go off stimulation for six weeks, and be reassessed whether subluxation is redeveloping.~If a subject in either group does not respond sufficiently to phase 1 therapy, the participant will move to phase 2 where the shoulder will be stimulated at up to 25 pps either with surface stimulation (SE group) or BION stimulation (BE group) for another six weeks. At the end of phase 2, participants will go off stimulation for six weeks and then be reevaluated.
Study NCT02459158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ME1100 inhalation solution
Description: Low dose of ME1100 inhalation solution twice daily for up to 14 days to be administered via eFlow nebulizer system
Study NCT02459158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ME1100 inhalation solution
Description: High dose of ME1100 inhalation solution twice daily for up to 14 days to be administered via eFlow nebulizer system
Study NCT03565068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8189
Description: MK-8189 4 mg tablet(s) will be administered orally QD for a total daily dose of 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 36 mg or 48 mg.
Study NCT03489018 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PCV10
Description: Experimental arms will receive a lower dose of the intervention than the marketed dose.
Study NCT03565068 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: MK-8189 dose-matching placebo tablets will be administered orally QD.
Study NCT03565068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Background AAP Therapy
Description: Participants with schizophrenia in Panel C will be on background therapy with an AAP medication (e.g., olanzapine, quetiapine, paliperidone, asenapine, iloperidone, aripirprazole, lurasidone, risperidone \[not to exceed daily dose of 6 mg\], or ziprasidone) throughout the study. Participants should be on a stable and well tolerated treatment regimen for at least 2 months prior to screening. NOTE: clozapine is not allowed.